Sexual Assault Author: Carolyn J. Sachs, MD, MPH
Editorial changes - 2010-03-19
Author information and module status
Prevention
Screening
Diagnosis
Consultation for Diagnosis
Hospitalization
Non-drug Therapy
Drug Therapy
Patient Education
Consultation for Management
Follow-up
Tables
Figures
References
Glossary
What's New
Patient Information
Additional Resources
Tools
Glossary
3TC
lamivudine
AZT
zidovudine(also ZDV)
bid
twice daily
CDC
Centers for Disease Control and Prevention
DKA
diabetic ketoacidosis
DNA
deoxyribonucleic acid
FDA
Food and Drug Administration
GC
gonococcus
GHB
γ hydroxy butyrate
HAART
highly active antiretroviral therapy
HBIg
hepatitis B immunoglobulin
β-HCG
human chorionic gonadotropin β subunit
HIV
human immunodeficiency virus
im
intramuscular
IUD
intrauterine device
OB/GYN
obstetrician/gynocologist
OCP
oral contraceptive pill
PID
pelvic inflammatory disease
po
orally
PTSD
posttraumatic stress disorder
qid
four times daily
RPR
rapid plasma reagin
STD
sexually transmitted disease
tid
three times daily
VDRL
Venereal Disease Research Laboratory (test)
Carolyn J. Sachs, MD, MPH has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations.
Darren B. Taichman, MD, PhD, Editor, PIER, has received grant support from Actelion Pharmaceuticals Ltd , and honoraria for continuing medical education grand rounds and lectures given.

The information included herein should never be used as a substitute for clinical judgment and does not represent an official position of ACP. Because all PIER modules are updated regularly, printed web pages or PDFs may rapidly become obsolete. Therefore, PIER users should compare the date of the last update on the website with any printout to ensure that the information being referred to is the most current available.
PIER is copyrighted (c) 2010 by the American College of Physicians,
190 N. Independence Mall West, Philadelphia, PA 19106-1572, USA.